# Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

> **NCT00384891** · PHASE3 · TERMINATED · sponsor: **Medical Enterprises Europe B.V.** · enrollment: 190 (actual)

## Conditions studied

- Urinary Bladder Diseases
- Urinary Bladder Neoplasms
- Urinary Bladder Cancer
- Malignant Tumor of Urinary Bladder
- Urologic Diseases
- Urologic Neoplasms
- Neoplasms
- Neoplasms by Site

## Interventions

- **DEVICE:** Synergo + MMC
- **DRUG:** Bacillus Calmette-Guérin

## Key facts

- **NCT ID:** NCT00384891
- **Lead sponsor:** Medical Enterprises Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 190 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384891, "Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00384891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*